Respiratory Diseases and Microbiome Dysbiosis

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Microbiomes".

Deadline for manuscript submissions: 31 May 2026 | Viewed by 1374

Special Issue Editors


E-Mail Website
Guest Editor
First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Interests: human microbiome; dysbiosis; chronic inflammatory diseases; cancer; drug development; multi-omics; translational studies
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Resp Dept First ICU Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Interests: infections; asthma; COVID-19; smoking cessation; ergospirometry

Special Issue Information

Dear Colleagues,

Respiratory disorders encompass a variety of conditions that affect lung function and breathing. The airway microbiome consists of various microorganisms, such as bacteria, fungi, and viruses, that play a crucial role in respiratory health by protecting against pathogens and regulating immune responses. Research has shown that imbalances in this microbial community (dysbiosis) can disrupt homeostasis, further complicating respiratory infections and chronic diseases. Moreover, the gut microbiota plays a pivotal role in modulating systemic and pulmonary immunity through the gut–lung axis. However, intestinal and airway microbiome dysbiosis disturbs this bidirectional crosstalk and influences respiratory health by contributing to immune dysfunction, inflammation, and ultimately the exacerbation of respiratory illness and comorbidities such as allergies. Drugs commonly used to treat patients, including antibiotics and oral corticosteroids, have a strong effect on microbiota structure. Research on the gut–lung axis underscores the importance of microbial diversity and its systemic impact on clinical manifestations and therapeutic outcome. Understanding these interactions may pave the way for the development of novel biomarkers and microbiome-based therapies for the prevention and management of chronic respiratory diseases, addressing not only the severity of symptoms but also allergic reactions and other coexisting conditions.

This Special Issue aims to highlight the dynamics of the microbiome in respiratory diseases and set a rational basis for personalized strategies to improve patient health. To this end, we invite authors to submit research articles, reviews, or case reports on a wide range of topics related to microbiome dysbiosis, host–microbiome interactions, and microbiota-targeting therapeutics in the context of respiratory disorders.

Dr. Heleni Loutrari
Dr. Paraskevi Katsaounou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • upper and lower airway disorders
  • microbiome
  • inflammation
  • immune response
  • infections
  • allergies
  • dysbiosis
  • gut–lung axis
  • metagenomics
  • multi-omics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

28 pages, 732 KB  
Review
Chronic Rhinosinusitis at the Interface of Type 2 Inflammation, Epithelial Barrier Dysfunction, and Microbiome Dysbiosis
by Konstantinos Petalas and George N. Konstantinou
Microorganisms 2026, 14(2), 386; https://doi.org/10.3390/microorganisms14020386 - 6 Feb 2026
Cited by 1 | Viewed by 974
Abstract
Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease of the nasal and paranasal sinus mucosa with substantial impact on quality of life. Although atopy and/or allergic rhinitis frequently coexist with CRS, often alongside type 2-skewed inflammation, the extent to which allergic mechanisms define [...] Read more.
Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease of the nasal and paranasal sinus mucosa with substantial impact on quality of life. Although atopy and/or allergic rhinitis frequently coexist with CRS, often alongside type 2-skewed inflammation, the extent to which allergic mechanisms define a discrete CRS entity remains debated, in part due to inconsistent operational definitions and overlapping clinical phenotypes. In parallel, culture-independent sequencing studies have reframed CRS as a disorder of host–microbe interactions, with many cohorts reporting reduced sinonasal microbial diversity, enrichment of potentially pathogen taxa (including Staphylococcus aureus), and biofilm-associated community states. However, causality and directionality remain uncertain. In this narrative review, we synthesize evidence at the interface of epithelial barrier dysfunction, type 2 cytokine networks (IL-4/IL-13/IL-5), and microbiome dysbiosis, highlighting where data are consistent across studies versus where findings are heterogeneous or predominantly associative. We discuss representative allergy-associated CRS prototypes such as allergic fungal rhinosinusitis and central compartment atopic disease as clinical models to interrogate these interactions, while distinguishing them from non–IgE-mediated type 2 entities such as aspirin-exacerbated respiratory disease. We also summarize current data linking atopy to sinonasal microbial signatures and discuss emerging microbiome-directed interventions (topical probiotics, bacteriophages, and microbiota transfer concepts) alongside biologics and precision anti-inflammatory therapies. Finally, we highlight key knowledge gaps, including the limited endotype-resolved and longitudinal studies, variable allergic phenotyping in microbiome research, and the need for standardized definitions and biomarker-driven stratification to clarify clinical utility and to guide mechanism-informed therapeutic trials. Full article
(This article belongs to the Special Issue Respiratory Diseases and Microbiome Dysbiosis)
Show Figures

Figure 1

Back to TopTop